SAB Biotherapeutics, Inc. (NASDAQ:SABSW – Get Free Report) saw a significant decline in short interest in June. As of June 30th, there was short interest totaling 610 shares, a decline of 91.1% from the June 15th total of 6,872 shares. Based on an average daily volume of 7,586 shares, the days-to-cover ratio is currently 0.1 days.
SAB Biotherapeutics Stock Down 20.8%
Shares of SABSW stock traded down $0.00 during trading on Friday, hitting $0.01. The company had a trading volume of 160,556 shares, compared to its average volume of 48,969. The stock’s 50-day moving average is $0.02 and its two-hundred day moving average is $0.03. SAB Biotherapeutics has a 52 week low of $0.01 and a 52 week high of $0.18.
SAB Biotherapeutics Company Profile
SAB Biotherapeutics, Inc is a clinical-stage biopharmaceutical company specializing in the development of fully human polyclonal antibody therapeutics. The company’s core technology, known as the Transchromosomic (Tc) Bovine platform, leverages genetically engineered cattle to produce large volumes of human antibodies in response to targeted antigens. These antibodies are designed to treat a range of infectious diseases and immunological disorders, offering a complementary approach to monoclonal antibodies and traditional vaccines.
The company’s lead programs focus on combating high-priority pathogens, including emerging coronaviruses and other viral threats.
Featured Articles
- Five stocks we like better than SAB Biotherapeutics
- AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target
- Micron’s $250 Billion Bet Could Reshape the AI Memory Race
- Rocket Lab’s Stock Drop Comes With a Bullish Twist
- Amazon’s New Debt Deal Puts Its AI Spending Story on Trial
Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
